Natera, Inc. (NASDAQ:NTRA) is one of the best strong buy healthcare stocks to invest in. On February 24, Natera, Inc. (NASDAQ:NTRA) announced results from the SINERGY trial, a Phase 2 study in recurrent or metastatic head and neck squamous cell carcinoma, with the data recently presented in an oral plenary at the 2026 MHNCS. Management reported that 27 patients received initial treatment of either immunotherapy alone or in combination with chemotherapy in the trial, and based on Signatera ctDNA dynamics du ...

Danaher Corporation (NYSE:DHR) is one of the best strong buy healthcare stocks to invest in. Danaher Corporation (NYSE:DHR) announced on February 24 that its Board of Directors approved a regular quarterly cash dividend of $0.40 per share of its common stock, payable on April 24, 2026, to holders of record on March 27, 2026. In another development, the company announced on February 17 a definitive agreement to acquire Masimo Corporation, which is a leading specialty diagnostics provider of pulse oximetry a ...

Biodesix (NasdaqGM:BDSX) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsChris Brinzey - PartnerRobin Harper Cowie - CFOScott Hutton - CEOWilliam Ruby - Equity Research AssociateConference Call ParticipantsAndrew Brackmann - Equity Research AnalystJohn Wilkin - Equity Research Analyst of Diagnostics and Life Science ToolsKyle Mikson - Managing Director and Senior Research AnalystThomas Flaten - Senior Research AnalystOperatorStanding by. Welcome to the Biodesix 4th quarter 2025 earni ...

Financial Data and Key Metrics Changes - The reported revenue for Q4 2025 was $29.5 million, a 19% increase from $24.7 million in Q4 2024 [10] - Gross profit for Q4 2025 was $18.7 million, up 20% from $15.5 million in Q4 2024, with gross margins increasing to 63.2% from 62.7% [11] - The operating loss for Q4 2025 increased by 14% to $5.3 million compared to $4.6 million in Q4 2024 [11] - Net loss rose 31% to $8.9 million from $6.8 million in the prior year, driven by increased financial expenses [12] - Adjusted EBITDA for Q4 was -$2.1 million, compared to -$1.4 million in Q4 2024 [12] - Cash and cash equivalents as of December 31, 2025, were $29 million [12] Business Line Data and Key Metrics Changes - Total billable volume in Q4 was approximately 38,000 tests, with tissue-based tests decreasing by 5% and liquid-based tests increasing by 128% year-over-year [10] - The acquisition of ExoDx contributed to the growth in liquid-based tests, which include Select mdx, Resolve mdx, and ExoDx [10][34] Market Data and Key Metrics Changes - The company aims to balance revenue contributions from tissue and liquid tests, which previously saw tissue tests accounting for 85% of revenue [34] - The integration of ExoDx is expected to enhance the customer base and drive growth in both segments [34] Company Strategy and Development Direction - MDxHealth's strategy focuses on menu expansion, operational discipline, and customer experience, which are expected to drive sustained top-line growth [4][6] - The company is committed to integrating ExoDx and enhancing its sales organization to capitalize on the combined customer base [34] - The goal for 2026 is to achieve revenue guidance of $137 million to $140 million, reflecting a 28% year-over-year growth [34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver growth and profitability, emphasizing the importance of operational discipline and customer experience [3][14] - The integration of ExoDx is seen as a significant growth opportunity, with expectations for improved operational efficiencies and market leadership in prostate cancer diagnostics [6][16] Other Important Information - The company amended its earn-out payment to Exact Sciences, reducing the upcoming payment by nearly $20 million, providing additional financial flexibility [8] - The collaboration with the University of Oxford is expected to enhance the utility of the GPS test in clinical guidelines, further solidifying MDxHealth's market position [16] Q&A Session Summary Question: Tissue ASP decline and mix shift - Management confirmed that the decline in tissue ASP was due to a mix shift towards Confirm and noted that ASPs reflect Medicare rates [19] Question: EBITDA performance and cash flow - Management acknowledged the lower EBITDA and higher cash burn, attributing it to the integration of ExoDx and expressed confidence in achieving a 10% EBITDA margin by year-end [20][21] Question: 2026 revenue guidance assumptions - Management indicated that the guidance reflects balanced growth from both tissue and liquid segments, with significant contributions expected from the ExoDx acquisition [32][34] Question: Operating leverage and gross margin expectations - Management stated that they expect to maintain flat OpEx while achieving growth and indicated that gross margins are expected to remain in the low 60s, with aspirations for improvement [44][46]

Natera (NasdaqGS:NTRA) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsAlexey Aleshin - General Manager of Oncology and Chief Medical OfficerCasey Woodring - VP of Equity ResearchDaniel Markowitz - VP of Equity ResearchDoug Schenkel - Managing Director of Life Science Tools and DiagnosticsJohn Fesko - President and Chief Business OfficerMichael Brophy - CFORicki Levitus - Equity Research AssociateSolomon Moshkevich - President of Clinical DiagnosticsSteve Chapman - CEOConference Call ...

MDxHealth (NasdaqCM:MDXH) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Company ParticipantsJohn Fraunces - Managing Director of Investor Relations and Corporate CommunicationsKate Janson - Equity Research Associate of HealthcareMichael McGarrity - CEONelson Cox - Healthcare Equity Research AssociateRon Kalfus - Interim CFOConference Call ParticipantsBill Bonello - Senior Research AnalystOperatorGood day, welcome to the MDxHealth fourth quarter and full year 2025 earnings conference call. All particip ...

Natera (NasdaqGS:NTRA) Q4 2025 Earnings call February 26, 2026 04:30 PM ET Speaker10Welcome to Natera's 2025 fourth quarter financial results conference call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a Q&A session. To ask a question at that time, please press Star, followed by One on your touchtone phone. If anyone has difficulty hearing the conference, please press Star zero for operator assistance. As a reminder, this call is being rec ...

2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 37% over 2024 Exceeded 2025 guidance with full-year revenue of $344 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended Dec. 31, 2025.“We closed out an outst ...

Delivered 41% revenue growth and 83% gross margin in Q4 2025; Improved Net Loss by 52% and achieved first-ever Adjusted EBITDA positivity in Q4 2025; FY2026 Revenue Guidance of $106-112 million, mid-point reflects 23% growth; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the fourth quarter and year ended December 31, 2025 (fi ...

Mdxhealth Announces Fourth Quarter and Full-Year 2025 Financial Results Fourth quarter revenue growth of 19% to $29.5 million2025 revenue growth of 20% to $107.9 millionConference call with Q&A today at 4:30 PM EST / 22:30 CET IRVINE, California – February 26, 2026 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced its financial results for the fourth quarter and year ended December 31, 2025. Michael K. McGarrity, ...